Group 1 - The core viewpoint of the article emphasizes the transformation in the field of synthetic chemistry, shifting from traditional experience-driven methods to data-driven and intelligent-driven approaches, primarily through the integration of robotics and AI [2][5][6] - The "Synthesis Chemistry Research New Paradigm - Robotics and AI Symposium" held in Shanghai aims to promote the intersection of chemistry, artificial intelligence, and automation technology, fostering academic innovation and accelerating industrial application [2][4] Group 2 - The keynote speeches highlighted the necessity of evolving the research paradigm in synthetic chemistry, with a focus on enhancing research efficiency through advanced methods beyond traditional techniques [5][6] - Various experts presented their findings on how AI and automation are revolutionizing the development of catalytic materials, significantly reducing research timelines by over 50% [12] - The integration of AI with robotics is being explored to create intelligent autonomous experimental platforms, which aim to accelerate the discovery of new materials and enhance research capabilities across various industries [14][40] Group 3 - The symposium featured discussions on the challenges faced in applying AI in synthetic chemistry, such as data scarcity and the complexity of reactions, while emphasizing the need for a collaborative approach to build a comprehensive synthetic chemistry database [23] - A consensus was reached among participants on the importance of creating an open data ecosystem to overcome interdisciplinary barriers and enhance the synergy between academia and industry [49] - The closing remarks underscored the progress made in Chinese academic conferences and the collective commitment to embrace intelligent technologies for substantial contributions to global chemistry [56]

Core Insights - The article highlights the innovative development path of Shenzhen Jiyang Intelligent Technology Co., Ltd. in the battery manufacturing sector, emphasizing its role in the transformation of the new energy industry driven by the "dual carbon" goals [1][2] Industry Overview - The new energy industry in China is undergoing a profound transformation from scale expansion to quality improvement, with power batteries being a core component that directly affects industry competitiveness [1] - The Chinese new energy industry is the largest globally, yet it faces significant challenges in battery manufacturing, particularly in logistics, information flow, and energy flow, leading to inefficiencies and safety risks [1] Company Innovations - Jiyang Intelligent has over 800 patents, including 38 international patents, and has established a digital workshop standard system for lithium-ion battery manufacturing [2] - The company has developed advanced equipment such as high-speed laser ear forming machines and intelligent continuous winding machines, breaking foreign monopolies and achieving international advanced technical standards [2] - Jiyang Intelligent has implemented a three-tier safety system ("passive-active-intrinsic") to reduce the probability of thermal runaway in batteries to below 0.01% through AI visual inspection and the application of thermal insulation materials [2] Strategic Directions - The company is focusing on three strategic areas: developing self-learning flexible manufacturing systems, utilizing blockchain technology for carbon emission traceability throughout the battery lifecycle, and creating integrated continuous battery manufacturing equipment for the European market [3] - Jiyang Intelligent has transformed from a technology follower to a rule-maker in the industry within 15 years, actively participating in the formulation of over 70 power battery manufacturing standards [2][3] Future Vision - The ultimate goal of Jiyang Intelligent is to lead in creating a better life through machine innovation, contributing significantly to the global energy transition and high-quality development of China's manufacturing industry [3]

机器人ETF(562500)是全市场唯一规模破百亿、流动性最佳、覆盖中国机器人产业链最全的机器人主题 ETF，助力投资者一键布局中国机器人产业。 2、近日，DeepMind旗下的药物研发公司Isomorphic Labs正准备开始在人体上测试其人工智能设计的药 物。Isomorphic Labs于2021年从DeepMind分拆出来，一直处于将AI融入药物研发的前沿。该公司利用 先进的机器学习算法分析海量生物数据，识别潜在的药物靶点，并设计出能够有效治疗多种疾病的新型 化合物。 3、7月7日，北京人形机器人创新中心正式发布开源运动控制框架Tien Kung-Lab，将机器人马拉松冠军 的运控算法面向行业开源，填补高性能人形机器人运动控制框架在开源领域的空白，为工业场景、物流 场景与特种作业场景等高复杂环境下规模化应用提供核心基础技术支撑。 【机构观点】 中银证券（601696）认为，脑机接口技术的发展延伸至人形机器人领域后，有望开创新的人机交互模 式，实现对复杂动作的控制。伴随着人形机器人核心零部件灵巧手的发展，有望解决人形机器人的运动 控制瓶颈。 【热门ETF】 【市场复盘】 本周一(7月7日)，截至收盘， ...

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [2] Core Insights - The pharmaceutical and biotechnology industry index increased by 5.30%, outperforming the CSI 300 index which rose by 3.52% during the reporting period [3][14] - The PE ratio (TTM, excluding negative values) for the pharmaceutical and biotechnology industry as of July 4, 2025, is 28.52x, up from 27.28x in the previous period, indicating an upward trend in valuation [3][19] - Notable sub-industries include "Other Biological Products" and "Medical R&D Outsourcing," which saw increases of 11.20% and 9.37% respectively, while "Medical Equipment" and "Blood Products" lagged with increases of only 0.98% [3][14] Industry Trends - The report highlights significant policy measures from the National Healthcare Security Administration and the National Health Commission aimed at supporting the high-quality development of innovative drugs [5][6] - The introduction of a commercial health insurance innovative drug directory is a key breakthrough, facilitating better pricing and reimbursement mechanisms for high-value drugs [6] - The report emphasizes the importance of the innovative drug industry chain, particularly focusing on platform pharmaceutical companies, clinical CROs, and high-barrier CDMOs [6] Important Industry News - The approval of several innovative drugs, including "ZEGFROVY" by Dize Pharmaceutical and "TQG203" by Zhengda Tianqing, marks significant advancements in the industry [41][42][46] - The report notes that the global number of hemophilia patients is expected to increase by 25% by 2025, highlighting the growing market for innovative treatments [42] - The approval of "Mastrudep" by Innovent Biologics for weight management in adults showcases the expanding therapeutic applications of GLP-1R/GCGR dual agonists [49][50] Investment Recommendations - Continuous attention is recommended for the innovative drug industry chain, particularly for companies that can navigate the new dual directory system and have international expansion capabilities [6] - The report suggests that the recent policy changes and the successful IPO of a biotech company signal a positive outlook for the innovative drug sector [6]

Core Viewpoint - Shenzhen's Futian District is actively enhancing its foreign investment attraction and business stability efforts, aiming to become a preferred destination for international capital [1][4] Group 1: Foreign Investment Growth - Futian District currently hosts 17,500 foreign enterprises, leading the city in the number of multinational company headquarters recognized in the latest round of applications [1] - From January to May this year, 1,039 new foreign enterprises were established in Futian, representing a year-on-year growth of 28.91% and accounting for 23.57% of the city's total new foreign enterprises [1] Group 2: Foreign Business Service Initiatives - The newly established Foreign Business Service Station in March aims to create a comprehensive service network for foreign enterprises, providing a one-stop service for investment, policy consultation, and business operations [1][2] - The service station has completed 126 consultation services and hosted 8 events focused on policy promotion and investment financing, serving over 50 foreign enterprises [1] Group 3: Service Ecosystem Development - Futian District is building a "1+10+N" foreign investment service ecosystem, which includes one district-level service station, ten street-level service points, and multiple foreign enterprise headquarters [3] - The district's strategic location near Hong Kong and the establishment of the Hong Kong-Shenzhen Innovation and Technology Cooperation Zone enhance its attractiveness for foreign investment [3] Group 4: Policy and Talent Support - Recent policy documents have been issued to strengthen the district's appeal to foreign investment, including a three-year plan to improve living and working conditions for expatriates and create a comprehensive foreign investment service ecosystem [4] - Futian has also upgraded its talent policies, launching initiatives to support international talent and establishing the first international talent station in the Guangdong-Hong Kong-Macao Greater Bay Area [4]

Core Viewpoint - Strong Brain Technology and Xilinmen (603008) have officially signed an exclusive strategic cooperation agreement and launched the world's first co-branded mattress product "Baobao BrainCo" that incorporates brain-machine and EEG technology [1] Group 1: Strategic Cooperation - The partnership marks Strong Brain Technology's first introduction of cutting-edge brain-machine interface technology into the traditional mattress industry [1] - The collaboration aims to create a new paradigm of AI mattress human-machine interaction [1] Group 2: Future Prospects - Strong Brain Technology plans to open more technological application channels to accelerate the commercialization of brain-machine interface technology in smart home and other fields [1]

Group 1 - The core viewpoint of the article highlights that Hongshang Asset has conducted research on Baicheng Pharmaceutical, focusing on its dual development strategy of innovative and generic drug research [1] - Baicheng Pharmaceutical is actively seeking new business growth points and has a wide range of innovative drug research projects in critical medical fields such as oncology, autoimmune diseases, neuropsychiatric disorders, and respiratory diseases [1] - The company is advancing several key projects, including the small molecule innovative drug BIOS-0635 for tumor treatment and multiple large molecule innovative drugs, with a strong emphasis on developing a drug targeting the KT6 site for solid tumors [1] Group 2 - Baicheng Pharmaceutical has established multiple mature organoid models for evaluating the efficacy of anti-tumor drugs, personalized precision medicine, and drug toxicity prediction [1] - The company has a new drug research platform that encompasses several key technology platforms, with a team of over 200 people, of which more than 80% hold master's or doctoral degrees [1] - The market potential for the 0618 target, which addresses osteosarcoma (OS) and neuropathic pain, is significant, especially given the large number of OS patients [1] Group 3 - Hongshang Asset was founded in October 2013, in collaboration with Sequoia Capital, and is recognized as a prominent private equity fund company in China [2] - The company focuses on absolute return goals in equity investment strategies, driven by fundamental research capabilities [2] - The investment research team at Hongshang Asset includes experienced professionals from large fund companies and award-winning analysts, ensuring robust management and industry influence [2]

在科技创新驱动发展的时代浪潮下，轻资产、重研发的科技型企业常因传统贷款模式限制面临融资困 境。上海易维视科技有限公司(以下简称"易维视")专注裸眼3D技术研发，其产品已在全国300多家医疗 机构应用，却因处于发展初期，面临研发资金不足的"卡点"。"质量标准贷"的出现，为这类企业带来了 新的曙光。 "'质量标准贷'让我们得以凭借技术优势、标准创新能力等获得授信，极大缓解了资金压力。"易维视董 事长方勇感慨道。2025年初，易维视将获得的贷款资金投入核心技术攻关，成功突破医用多人裸眼3D 影像处理与显示系统等关键技术，并实现新产品在多个领域的集中发布。"融资门槛降低，审批流程加 快，这笔资金对产品研发起到了关键性推动作用。"方勇进一步表示。 截至目前，虹口"质量标准贷"已取得显著成效，成功为建工电商、高顿教育、医东网络等8家企业完成 质量融资授信，授信额度近3亿元。更值得关注的是，获得"质量标准贷"授信的企业，在符合条件的情 况下，还能叠加享受知识产权质押融资、"虹企贷"等政策支持，进一步拓宽了融资渠道，增强了政策使 用的灵活性。 接下来，虹口区市场监管局将在与农商银行虹口支行、交通银行虹口支行签订战略合作协议的 ...

Core Viewpoint - The rapid development of the global innovative drug industry has led to a significant opportunity for the CDMO (Contract Development and Manufacturing Organization) sector, with Shanghai Haoyuan Pharmaceutical Co., Ltd. positioning itself as a leader in the ADC (Antibody-Drug Conjugate) niche [1][2]. Group 1: Company Strategy and Market Position - Haoyuan Pharmaceutical has identified ADC as a key area for growth, establishing core competencies and positioning itself in the first tier of CDMO providers in this field [1][2]. - The company has successfully undertaken over 110 ADC projects in 2024, with 12 small molecule products related to ADC having completed FDA filings [2]. - The company reported a revenue of 2.254 billion yuan in 2024, a year-on-year increase of 20.62%, and a net profit of 202 million yuan, up 58.17% year-on-year [2]. Group 2: Technological Advancements - ADC technology, which combines antibodies, linkers, and cytotoxic drugs, allows for targeted cancer treatment, minimizing damage to normal tissues [2]. - Haoyuan Pharmaceutical has developed proprietary technologies in ADC, having been a pioneer in this field since its establishment in 2006 [3]. - The company has collaborated with AI pharmaceutical firms to enhance drug development processes, establishing an AI Drug Exploration Joint Laboratory with East China Normal University [3]. Group 3: International Expansion - The company is actively expanding its international market presence, having serviced numerous ADC "outbound" orders, with nine overseas licensing transactions reported in the first half of the year [4]. - Haoyuan Pharmaceutical has established a CDMO base in Chongqing, which is the largest of its kind in Southwest China, and has passed EU quality audits to facilitate international market expansion [4][5]. - The company has set up business warehousing centers in the US, Europe, and India, serving over 13,000 pharmaceutical companies and research institutions globally [5]. Group 4: Future Prospects - Haoyuan Pharmaceutical is not only focusing on ADC but is also exploring emerging fields such as PDC (Peptide-Drug Conjugates), RDC (Radioisotope-Drug Conjugates), and ApDC (Aptamer-Drug Conjugates) [5]. - The company aims to create a full-chain service model that integrates technology research, industrialization, and global service, thereby establishing competitive barriers [5].

1. Report Industry Investment Rating No relevant content provided. 2. Core Viewpoints of the Report - The 6 - month PMI data continued to improve slightly in June, indicating a stabilizing trend in China's economy. Sino - US trade situation has positive news, but there are still uncertainties in external demand due to ongoing US trade negotiations. The CSI Convertible Bond Index has reached new highs. Although most institutions' holding face - values of convertible bonds have slightly declined, considering the impact of bank convertible bond conversions on the overall scale, their actual willingness to reduce positions is weak, and the allocation demand for convertible bonds remains strong. The supply - demand contradiction of convertible bonds has intensified, and there is room for an increase in the convertible bond parity valuation [3][20]. - It is recommended to choose balanced convertible bonds with high - volatility underlying stocks that can quickly consume the premium rate or high - price, low - premium and non - redeemable equity - biased convertible bonds in the short term. For those with high requirements for drawdown, reducing positions can be considered. In July, attention should be paid to sectors such as consumer (appliances, auto parts, two - wheeled vehicles), technology (PCB, copper - clad laminates, data center power supplies in the computing power industry chain), grid equipment, sea wind, energy storage, innovative drugs, and some chemical pharmaceuticals with stable volume and price [4][21]. 3. Summary by Relevant Catalogs 3.1 Market Focus Last Week (June 30 - July 4, 2025) Stock Market - The equity market fluctuated and rose last week. Sectors with over - capacity reduction expectations such as steel, building materials, and photovoltaic performed well, and the innovative drug sector led the gains. The high - dividend bank sector also performed well. The A - share market showed different trends each day, with changes in sector performance and trading volume [1][9]. - Most Shenwan primary industries closed higher. Steel (+5.06%), building materials (+3.96%), banks (+3.77%), pharmaceutical biology (+3.64%), and comprehensive (+2.82%) led the gains, while computer (-1.28%), non - bank finance (-0.72%), beauty care (-0.55%), and transportation (-0.20%) performed poorly [10]. Bond Market - The bond market fluctuated last week. After the quarter - end, the liquidity tightened. The second - quarter monetary policy implementation report mentioned observing and evaluating the bond market from a macro - prudential perspective. The slight recovery of the June PMI and the increase in market risk appetite suppressed bond market sentiment. The 10 - year Treasury bond yield closed at 1.64% on Friday, down 0.29bp from the previous week [1][10]. Convertible Bond Market - Most convertible bond issues closed higher. The CSI Convertible Bond Index rose 1.21% for the whole week, the median price increased 1.10%, the calculated arithmetic average parity increased 1.82%, and the overall market conversion premium rate decreased 1.57% compared with the previous week. The arithmetic average conversion premium rates of convertible bonds with parities in the ranges of [90,100), [100,110), and [110,120) changed by +1.71%, +2.27%, and -0.79% respectively, at the 68%, 77%, and 39% percentile values since 2023 [2][10]. - Most industries in the convertible bond market closed lower. Pharmaceutical biology (+2.49%), national defense and military industry (+1.85%), environmental protection (+1.70%), and public utilities (+1.59%) led the gains, while transportation (-1.07%), textile and clothing (-0.84%), automobile (-0.41%), and communication (-0.33%) performed poorly [14]. - In terms of individual bonds, Seli (innovative drugs), Huicheng (hazardous waste treatment), Jing 23 (PCB), Emergency (military industry), and Xingang (thermal production and supply) convertible bonds led the gains; Sanyang (automobile logistics services), Jinji (H - acid reactive dyes), Jingduan (precision gears & announced forced redemption), Huafeng (automobile electronic control systems & announced forced redemption), and Huitong (modified plastics & announced forced redemption) convertible bonds led the losses [2][15]. - The total trading volume of the convertible bond market last week was 323.83 billion yuan, with an average daily trading volume of 64.766 billion yuan, an increase from the previous week [18]. 3.2 Valuation Overview As of July 4, 2025, the average conversion premium rates of equity - biased convertible bonds with parities in the ranges of 80 - 90 yuan, 90 - 100 yuan, 100 - 110 yuan, 110 - 120 yuan, 120 - 130 yuan, and above 130 yuan were 40.92%, 30.48%, 23.07%, 12.75%, 8.96%, and 5.65% respectively, at the 85%/72%, 82%/68%, 84%/77%, 63%/35%, 62%/39%, and 71%/42% percentile values since 2010/2021. The average YTM of bond - biased convertible bonds with parities below 70 yuan was -0.72%, at the 4%/0% percentile values since 2010/2021. The average implied volatility of all convertible bonds was 33.78%, at the 64%/44% percentile values since 2010/2021. The difference between the convertible bond implied volatility and the long - term actual volatility of the underlying stock was -13.81%, at the 25%/31% percentile values since 2010/2021 [22]. 3.3 Primary Market Tracking Last Week (June 30 - July 4, 2025) - Libo Convertible Bond was announced for issuance, and Dianhua and Anke Convertible Bonds were listed. - Libo Convertible Bond (111023.SH): The underlying stock is Libote (605167.SH) in the building decoration industry, with a market value of 5.155 billion yuan as of July 4. The company focuses on the design and manufacturing of industrial modules. The issued convertible bond scale is 750 million yuan, and the funds after deducting issuance fees will be used for the large - scale industrial module manufacturing project of Nantong Libote Heavy Industry Co., Ltd [30]. - Dianhua Convertible Bond (127109.SZ): The underlying stock is Xiangtan Dianhua (002125.SZ) in the power equipment industry, with a market value of 8.555 billion yuan as of July 4. The company's main businesses include the production and sales of electrolytic manganese dioxide and new - energy battery materials, etc. The issued convertible bond scale is 487 million yuan, and the funds will be used for the 30,000 - ton spinel - type lithium manganate battery material project and to supplement working capital [31]. - Anke Convertible Bond (123257.SZ): The underlying stock is Anke Innovation (300866.SZ) in the electronics industry, with a market value of 61.207 billion yuan as of July 4. The company is mainly engaged in the R & D and sales of smart mobile peripherals, etc. The issued convertible bond scale is 1.105 billion yuan, and the funds will be used for multiple projects such as R & D and industrialization of portable and household energy - storage products [32]. - As of July 4, the exchange accepted Shenyu Co., Ltd., and there were no new enterprises approved for registration, passed by the listing committee, passed by the general meeting of shareholders, or with board of directors' plans. There are currently 77 convertible bonds to be issued, with a total scale of 123.22 billion yuan, including 4 approved for registration with a total scale of 9.01 billion yuan and 3 passed by the listing committee with a total scale of 2.62 billion yuan [33]. Future Week (July 7 - July 11, 2025) As of the announcement on July 4, there are no convertible bonds announced for issuance or listing in the coming week [33].